Erik van Zandbergen

Erik van Zandbergen
Chief Operating Officer
Erik joined Julius Clinical in January 2019. His primary drive is to get new therapies to patients through impeccable service delivery to clients.
Related
Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requi...
Getting GRIP on NASH: Implementation of an international screening program
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program. During this presentat...
NAFLD: patient identification strategies
In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...